Doctor: Many prostate cancer screenings involve only a blood test
"It's not a death sentence, it's a life sentence," said Dr. Michael Lutz. "It's important to get screened and know if you're at risk."
Big picture view
Lutz, the president of the Michigan Men's Health Foundation, says there is plenty of living to do after a prostate cancer diagnosis. You have to catch it early.
Who's at greatest risk?
"We know there are certain men at risk," he said, "Family history, African American, firefighter, fighter pilot - these are going to increase risk."
Screening for prostate cancer involves a blood test, the PSA and now Dr. Lutz says the slightly uncomfortable part of the exam, might not be needed.
"A lot of men don't want to get screened because of the digital rectal exam rather get a rectal exam - they would rather get bit by cobra," Lutz said. "Get the PSA blood test first. If its low you don't need rectal exam."
For those at higher risk, screening can start at 40. Those with average risk it's recommended men start screenings at 50.
But the recommendations get murky when it comes to men over the age of 70. Lutz says be your own advocate and ask for the screening no matter your age.
"Don't let your chronological age be your determining factor," he said.
This weekend, on Father's Day - the Run for the Ribbon is happening at the Detroit Zoo. Everyone is welcome to celebrate survival of prostate cancer.
Get more info by tapping HERE.Then in September - get ready for the annual Men's Health Event at Ford Field. Some of the money raised at run for the ribbon will fund the Men's Health Event at Ford Field.
That's an incredible event that offers life-changing screenings.
The Source
This report was based off an interview with Dr, Michael Lutz.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Don't Reclassify Grade Group 1 Prostate Cancer: New Data
TOPLINE: Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding suggests that GG1 prostate cancer should not be reclassified as noncancerous, as some experts have proposed. METHODOLOGY: Some experts have pushed to reclassify GG1 prostate cancer as a noncancerous entity to help reduce overtreatment. GG1 status is primarily designated via biopsy, but current guidelines recommend treatment decisions be based on a range of parameters, including prostate-specific antigen (PSA) levels, clinical stage, and tumor volume. Arguing against reclassification, researchers analyzed how localized GG1 prostate cancer varies by National Comprehensive Cancer Network (NCCN) risk groups, treatment, and cancer-specific outcomes. The researchers used the Surveillance, Epidemiology, and End Results database to identify 117,162 men diagnosed with localized GG1 prostate cancer (median age, 64 years) between January 2010 and December 2020. Patients were stratified by NCCN risk groups: low-risk, favorable intermediate-risk (n = 10,440; 9%), unfavorable intermediate-risk (n = 3145; 3%), and high-risk (n = 4539; 4%) — meaning 16% had non-low-risk disease. Outcomes included adverse pathology (> pT3, GG3-5 or pN+) at radical prostatectomy, prostate cancer-specific mortality, and trends in the management of GG1 prostate cancer. Comparisons with SEER patients with GG2 disease were included for context. The median follow-up was 58 months. TAKEAWAY: Rates of adverse pathology at prostatectomy increased from 16% in low-risk GG1 disease to 60% in high-risk GG1 disease. In adjusted analyses, compared with low-risk prostate cancer, favorable intermediate-risk GG1 prostate cancer was associated with 1.42-fold higher odds of adverse pathology, unfavorable intermediate-risk GG1 with 2.31-fold higher odds, and high-risk GG1 with 7.15-fold higher odds. At 10 years, the cumulative incidence of prostate cancer-specific mortality was 1.3% for low-risk GG1, 2.0% for favorable intermediate-risk GG1, 2.4% for unfavorable intermediate-risk GG1, and 4.7% for high-risk GG1. Compared with low-risk GG1 disease, the risk for death from prostate cancer was higher for favorable intermediate-risk (adjusted hazard ratio [aHR], 1.60), unfavorable intermediate-risk (aHR, 2.10), and high-risk (aHR, 3.58) GG1 prostate cancer. Mortality rates among patients with intermediate-risk GG1 cancer were comparable to that of patients with favorable intermediate-risk GG2 disease, at 2.1%. However, mortality among high-risk GG1 patients (4.7%) was significantly higher (P < .001). Regarding trends in the management of GG1 prostate cancer, active surveillance rose from 4% to 19% for unfavorable intermediate-risk disease, and from 9% to 25% for high-risk disease (P < .001). The data suggest high-risk patients are being undertreated, the authors wrote, 'possibly due to conflation of grade and risk.' IN PRACTICE: Prostate cancer-specific mortality for men with GG1 disease 'increases substantially across National Comprehensive Cancer Network risk groups,' the authors concluded. 'Designating GG1 on biopsy as noncancer without considering the prognostic values of adverse clinical features may lead to undertreatment and an increased risk of cancer-specific death in men with non-low-risk disease.' SOURCE: The study, led by Neal A. Patel, MD, Weill Cornell Medicine, New York City, was published online in JAMA Oncology. LIMITATIONS: Analysis lacked data on MRI and targeted biopsy use and did not account for prostate volume, which affects PSA levels. Histologic grading varied across pathologists due to nonstandardized assessments. Additionally, details on active surveillance intensity and watchful-waiting protocols were unavailable. DISCLOSURES: The study received support from the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust and the Sandra and Edward Meyer Cancer Center of Weill Cornell Medicine. One author reported serving on the advisory board for Lantheus, Lynx Dx, Pacific Edge, and Pfizer/Astellas and receiving grants from the National Cancer Institute outside the submitted work. No other conflicts of interest were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Newsweek
4 days ago
- Newsweek
Kids Who Eat More Fruit and Vegetables Share Key Character Trait
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Children who are caring and kind may be more likely to develop healthy eating habits in adolescence, a new study has found. The findings, published in the American Journal of Preventive Medicine, indicate that encouraging so-called "prosocial behavior" during childhood could serve as a potential approach to support healthy eating habits. Researchers led by social epidemiologist professor Farah Qureshi of Johns Hopkins Bloomberg School of Public Health analyzed data from the UK's Millennium Cohort Study—a nationally representative longitudinal study that tracked children from birth through adolescence. By examining data from children aged five to 17, researchers found a consistent and meaningful link between prosocial behaviors—like caring for others, cooperating and helping—and greater consumption of fruits and vegetables during the teen years. "Too often, we focus on what is going wrong in young people's lives," Qureshi said. "But what we hear from them time and time again is that they are tired of that narrative. They want us adults to pay more attention to what is going right." Smiling loving African American mother and little daughter prepare healthy delicious salad in kitchen. Smiling loving African American mother and little daughter prepare healthy delicious salad in kitchen. fizkes According to the study's findings, kids who were regularly described by parents as helpful and kind at ages five, seven and 11 were more likely to report healthier dietary habits at 14 and 17. The researchers suggest that these prosocial tendencies could provide psychological benefits—like improved mood and resilience—that help drive better decision-making around food. "Prosocial behaviors... can influence health by strengthening children's social ties and improving psychological functioning," explained senior author and psychologist professor Julia K. Boehm of Chapman University. She added: "All of these, in turn, serve as resources that may inform health-related choices, as is evidenced by our latest findings." While the study adjusted for factors like socioeconomic status, parental marital status and earlier eating behaviors, the researchers acknowledge that some family dynamics may still have influenced the results. Still, the long-term data and large sample size make the findings particularly compelling. "Supporting prosociality in childhood may be a promising health promotion strategy for future consideration," said paper co-author and social and behavioral scientist professor Laura D. Kubzansky of the Harvard T.H. Chan School of Public Health. She called for more asset-based approaches that leverage children's strengths—like empathy, cooperation and compassion—in public health interventions. Dr. Qureshi put it simply: "This study offers us an important reminder about the power of kindness and compassion not only for those who receive it, but also for those who give it." Do you have a health story to share with Newsweek? Do you have a question about nutrition? Let us know via health@ Reference Qureshi, F., Woodward, K. P., Kubzansky, L. D., & Boehm, J. K. (2025). Kind kids, healthy teens: Child prosociality and fruit and vegetable intake. American Journal of Preventive Medicine.
Business Wire
04-08-2025
- Business Wire
American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity
SAN FRANCISCO--(BUSINESS WIRE)--The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision oncology company focused on improving access to cancer screening and advancing health equity. This collaboration supports ACS's nationwide cancer screening efforts, including the I Love You, Get Screened public awareness campaign; community-based health system partnerships; and state coalition work aimed at removing barriers to lifesaving screenings. ACS and Guardant Health aim to increase awareness, promote early detection, and improve outcomes for individuals in communities that have historically experienced limited access to preventive care. 'Regular cancer screening saves lives by finding certain cancers early, when they are often easier to treat or even prevent altogether,' said Maria Olson, Executive Vice President, American Cancer Society. 'With support from Guardant Health, we can reach more people across the Bay Area with the information, tools, and services they need to take action for their health.' Despite being a hub of healthcare innovation, California continues to fall behind the national average in key cancer screening rates. Data from the American Cancer Society shows that only 64% of California women aged 45 and older are up to date on screening mammograms, compared to 69% nationally. Colorectal cancer screening rates are also lower, with 60% of eligible Californians screened compared to 62% nationwide. These gaps represent a critical opportunity to expand access and close the screening disparity. In 2025, an estimated 2,041,910 people in the U.S. will be diagnosed with cancer, and more than 600,000 lives are expected to be lost due to cancer. However, due to reductions in smoking and advances in early detection and treatment, cancer mortality has dropped 34% from 1991 to 2022, averting approximately 4.5 million deaths during that time. This work aims to accelerate that momentum, with a special focus on communities that remain underserved. Guardant Health will support the following ACS initiatives: Expanding the reach of the I Love You, Get Screened campaign, which garnered over 313 million impressions in 2024 and delivers culturally relevant education to communities including Black/African American, Hispanic/Latino, and LGBTQ+ populations. Promoting digital tools on including a locator tool that helps individuals find more than 15,000 screening locations across the U.S. Supporting community health interventions, such as patient education, navigation to screening appointments, transportation support, and language access services. These efforts contributed to over 555,000 completed screenings and 7,800 cancers detected in 2024. Collaborating with state coalitions, including those in California, to implement localized strategies that help increase screening rates and reduce disparities. 'Guardant Health is proud to partner with the American Cancer Society in the fight to expand cancer screening access,' said AmirAli Talasaz, Guardant Health co-founder and co-CEO. 'We share a commitment to ensuring that everyone, regardless of race, ethnicity, income, or ZIP code, has access to convenient and timely cancer screening, so we can detect cancer earlier and give them the opportunity for a better outcome.' Throughout 2025, ACS will engage communities across the nation through impactful campaigns aligned with key cancer awareness months—including cervical cancer awareness in January, colorectal in March, prostate in September, breast in October, and lung in November. These efforts will feature personal stories, local events, and trusted education to empower more people to get screened and take charge of their health. To learn more about ACS screening tools or to find a local screening center, visit About the American Cancer Society The American Cancer Society is a leading cancer-fighting organization with a vision to end cancer as we know it, for everyone. For more than 110 years, we have been improving the lives of people with cancer and their families as the only organization combating cancer through advocacy, research, and patient support. We are committed to ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. To learn more, visit or call our 24/7 helpline at 1-800-227-2345. Connect with us on Facebook, X, and Instagram. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook.
